{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T04:38:22.603428+00:00","company":{"ticker":"BFRI","cik":1858685,"company_name":"Biofrontera Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"c11de82306d3c83b38945a4b35ccb623155811c0","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2026-01-07T23:59:59+00:00","payload":{"company_response":"The Company intends to actively monitor the closing bid price of its common stock and, as appropriate, will consider available options to resolve the deficiency and regain compliance with the Nasdaq Listing Rules.","compliance_status":"deficient","cure_deadline":"2026-06-30","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 closing bid price for 10 consecutive business days","notice_date":"2025-12-31","notice_type":"deficiency_notice","plan_due_date":"2026-06-30","raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in\ncompliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s\ncommon stock was less than $1.00 per share for the previous 34 consecutive business days. The\nnotice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-000823","anchor_url":"https://secwatch.observer/filing/0001493152-26-000823#claim-c11de82306d3c83b38945a4b35ccb623155811c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226000823/0001493152-26-000823-index.htm"},{"fact_type":"ma_transaction","fact_key":"f3ebbf89df88eb178cd11dde793e6a2acc92e8af","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2025-11-07T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-11-06","consideration_text":"maximum of $10,000,000","counterparty":"Pelthos Therapeutics Inc.","effective_date":"2025-11-06","item_codes_triggered":["2.01"]},"claim":"Biofrontera Inc. completed a disposition involving Pelthos Therapeutics Inc. for maximum of $10,000,000 (closed 2025-11-06).","evidence_excerpt":"Capitalized terms used below that are not defined herein shall have the meanings ascribed\nto such terms in the APA. The\npurchase price for the Acquired Assets is a maximum of $10,000,000, payable as follows: 1) $3,000,000\n in cash, paid on the Closing Date; 2) Subject\n to availability of certain commercial quantities of the Product and other terms and conditions of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-021189","anchor_url":"https://secwatch.observer/filing/0001493152-25-021189#claim-f3ebbf89df88eb178cd11dde793e6a2acc92e8af","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/0001493152-25-021189-index.htm"},{"fact_type":"earnings_release","fact_key":"300ea42c7480a2ee52cf5539019956b0dc21fb0b","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$(2.88) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$10.4 million, or $(2.88) per share","period_text":"the three months ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$7.9 million"},"claim":"Biofrontera Inc. reported the three months ended March 31, 2024 results: revenue $7.9 million, net income $10.4 million, or $(2.88) per share, EPS $(2.88) per share.","evidence_excerpt":"2024 and provided\na business update. Highlights\nfrom the first quarter of 2024 and subsequent weeks included the following: ● Total\n revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period\n of the prior year primarily driven by reimbursement headwinds our customers experienced due\n to the Change Healthcare data breach ● Cash\n and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-020031","anchor_url":"https://secwatch.observer/filing/0001493152-24-020031#claim-300ea42c7480a2ee52cf5539019956b0dc21fb0b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm"},{"fact_type":"governance_change","fact_key":"57ef95d12897cdc583184cab3810a5e13fc0d08d","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-04-25","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 15,000,000 to 35,000,000"},"claim":"Biofrontera Inc.: Increased authorized shares of common stock from 15,000,000 to 35,000,000 (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, Biofrontera Inc. (the “Company”) filed a Certificate of Second Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.001, from 15,000,000 to 35,000,000.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017255","anchor_url":"https://secwatch.observer/filing/0001493152-24-017255#claim-57ef95d12897cdc583184cab3810a5e13fc0d08d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224017255/0001493152-24-017255-index.htm"},{"fact_type":"earnings_release","fact_key":"251983b2b10ae5ac83d82713eb5f15ff8837004c","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"eps_text":"$1.65 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$3.5 million","period_text":"the fourth quarter of 2023","report_date":"2024-03-15","result_type":"reported_results","revenue_text":"$10.6 million"},"claim":"Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.","evidence_excerpt":"Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-010152","anchor_url":"https://secwatch.observer/filing/0001493152-24-010152#claim-251983b2b10ae5ac83d82713eb5f15ff8837004c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm"},{"fact_type":"earnings_release","fact_key":"409a0248ce22cf2f13dcd0d402e22f9baac32a30","cik":1858685,"ticker":"BFRI","company_name":"Biofrontera Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and twelve months ended December 31, 2023","report_date":"2024-03-15","result_type":"reported_results","revenue_text":null},"claim":"Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.","evidence_excerpt":"On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-010152","anchor_url":"https://secwatch.observer/filing/0001493152-24-010152#claim-409a0248ce22cf2f13dcd0d402e22f9baac32a30","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm"}]}